Login / Signup

Neuroaxonal damage in natalizumab-treated MS patients: The role of JCV antibody titres.

Gloria D CostaLetizia LeocaniMarco PisaTommaso CroeseVittorio MartinelliMoiola LFrancesca SangalliBruno ColomboAiden HaghikiaRalf GoldRoberto FurlanGiancarlo Comi
Published in: Multiple sclerosis (Houndmills, Basingstoke, England) (2024)
These findings indicate a potential link between JCV burden and neuroaxonal degeneration in natalizumab-treated MS patients.
Keyphrases
  • multiple sclerosis
  • end stage renal disease
  • newly diagnosed
  • ejection fraction
  • chronic kidney disease
  • mass spectrometry
  • prognostic factors
  • peritoneal dialysis
  • ms ms
  • risk assessment
  • risk factors
  • patient reported